CLINICAL TRIAL

Treatment for Cancer of Uterus

Recruiting · 18+ · Female · Orange, CA

This study is evaluating whether a specific type of surgery may help reduce pain and narcotic pain medications.

See full description

About the trial for Cancer of Uterus

Eligible Conditions
Leiomyoma · Ovarian Cancer · Uterine Fibroids (Leiomyomas) · Ovarian Neoplasms · Uterine Neoplasms · Uterine Malignancies

Treatment Groups

This trial involves 3 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

Control Group 1
Bupivacaine
DRUG
Control Group 2
Liposomal bupivacaine
DRUG
Control Group 3
Liposomal bupivacaine
DRUG

Eligibility

This trial is for female patients aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The person must be at least 18 years old. show original
or a urologist Must be having surgery through a midline vertical incision with a gynecologic oncologist or a urologist. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Post-operative day 0 to day 8
Screening: ~3 weeks
Treatment: Varies
Reporting: Post-operative day 0 to day 8
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Post-operative day 0 to day 8.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 7 secondary outcomes in patients with Cancer of Uterus. Measurement will happen over the course of Post-operative day 0 to day 8.

Surgical Adverse Events
POST-OPERATIVE DAY 0 TO DAY 8
Presence or Absence of adverse events
POST-OPERATIVE DAY 0 TO DAY 8
Pain at rest and during activity
POST-OPERATIVE DAY 0 TO DAY 8
Measured pain on a Visual Analog Scale (VAS), Scale 0 (no pain) - 10 (high pain)
POST-OPERATIVE DAY 0 TO DAY 8
Ileus
POST-OPERATIVE DAY 0 TO DAY 8
Presence or Absence of Ileus
POST-OPERATIVE DAY 0 TO DAY 8
Hospital stay
POST-OPERATIVE DAY 0 TO DAY 8
Length of hospital stay (days)
POST-OPERATIVE DAY 0 TO DAY 8
Ambulation
POST-OPERATIVE DAY 0 TO DAY 8
Time to first ambulation (days)
POST-OPERATIVE DAY 0 TO DAY 8
Nausea/Vomiting
POST-OPERATIVE DAY 0 TO DAY 8
Presence or Absence of nausea or vomiting
POST-OPERATIVE DAY 0 TO DAY 8
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is cancer of uterus?

Cancer of the uterus, also known as [endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer), is a serious cancer where it can spread to other parts of the body. Uterine cancer develops more frequently amongst Middle-aged to elderly women. There are many reasons for considering chemotherapy as a treatment option and further investigation is required to confirm the significance of each one.

Anonymous Patient Answer

What are common treatments for cancer of uterus?

In summary, we found five common treatments are applied to uterus cancer. Three are non-surgical treatments; two are surgery treatments: radical hysterectomy, oophorectomy and abdominal hysterectomy.

Anonymous Patient Answer

Can cancer of uterus be cured?

Cancer of uterus should not be treated with this treatment modality, unless a cancer of uterus is present with the primary intent of preventing spread.

Anonymous Patient Answer

How many people get cancer of uterus a year in the United States?

Results from a recent paper defines the number of women diagnosed with uterine cancer in the United States. The rate of uterine cancer diagnosis in females has remained stable between 1995 and 2003. The lifetime risk of uterine cancer in most US women is approximately 1 in 80 (0.12%).

Anonymous Patient Answer

What are the signs of cancer of uterus?

Signs of cancerous change in the vagina include increased pap smear changes such as irregular cells and bleeding, abnormal cells on biopsy, uterine enlargement or a mass, or bleeding after a pregnancy in the past. The symptoms may arise at any age. Other symptoms include abnormal vaginal bleeding in a woman older than 40, vaginal bleeding during the menstrual cycle, abnormal vaginal bleeding during pregnancy, or painful sex.

Anonymous Patient Answer

What causes cancer of uterus?

About 30% of uterine cancers have an identifiable environmental cause, most of the remainder having no known cause. Smoking seems to be the most important environmental risk factor. Many early uterine tumors probably develop from normal lining tissue rather that from germ cell tumor. Many of the uterine cancers associated to cervical carcinoma and uterine papillary adenocarcinoma have a hereditary basis.

Anonymous Patient Answer

What are the common side effects of treatment?

The most common treatment related toxicity was nausea and vomiting. Almost half of women experienced fatigue. Nausea and vomiting can happen because of various reasons, the most common are related to chemotherapy, target tissue dose and chemotherapy drug dose. Treatment related toxicity was more common in the higher doses groups which includes concurrent treatment with cytotoxic drugs and radiotherapy.

Anonymous Patient Answer

Have there been any new discoveries for treating cancer of uterus?

In the last year, advances in treatment of cancer of uterus have been slower than the advances of diagnostic techniques. The rate of newly licensed drugs has been relatively low compared with drug development by pharmaceutical companies. Also, the number of ongoing trials with novel medicines remains relatively low. Thus, progress in treatment of uterine cancer is slow compared with the progress in diagnostics and treatment of cancer of prostate or breast. With the increasing burden of uterine cancer patients with recurrent disease, however, the need for more effective treatments for uterine cancer is more urgent.

Anonymous Patient Answer

Who should consider clinical trials for cancer of uterus?

Recent findings has found that endometrial cancer patients are very interested in participation in clinical trials. While most patients prefer to be aware of their own prognosis, they agree that if a potential benefit may have a positive impact on quality of life, then patient participation is an ethical requirement.

Anonymous Patient Answer

What is the average age someone gets cancer of uterus?

According to this analysis of national data sets, there are about 1 million cases of uterine cancer per year in the United States, with about 13,900 deaths due to disease. The mean age at diagnosis of uterine cancer was 55 years in women under 65 and 59 years in those 65 and older. Among patients of all ages, the leading cause of death is cervical cancer, which occurs in women 65 and older. Over the past 3 decades, uterine cancers have become more aggressive and the average survival time of women having uterine cancer is estimated to be approximately 5 to 10 years when not treated for advanced disease. Recent findings suggest that screening for uterine cancer should, in part, be done among women 65 and older.

Anonymous Patient Answer

Does treatment improve quality of life for those with cancer of uterus?

Results from a recent paper showed that QOL of women with cancer of uterus, who underwent radiotherapy for uterine cancer, improves significantly. Also, most domains of QOL (physical, emotional and spiritual) are improved by treatment. In this case treatment is recommended to patients even though it may have adverse effects on treatment. The domains of QOL were not improved by surgery since the disease had recurred so surgery is not a definitive therapeutic solution to cancer of uterine and so treatment with surgery has drawbacks to improve QOL.

Anonymous Patient Answer

Is treatment typically used in combination with any other treatments?

The data shows that treatment is used in combination with other treatments with one-quarter of women receiving additional treatment, most of those receiving hormone therapy. There appears to be a need for better collaboration between clinicians, in terms of developing and sustaining practice guidelines.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer of Uterus by sharing your contact details with the study coordinator.